A Multicenter Expanded Access Program Protocol for Melphalan Flufenamide (melflufen) in Combination with Dexamethasone in Patients with Triple Class Refractory (TCR) Multiple Myeloma(MM) NCT04534322
Melphalan Flufenamide is an investigational agent and not currently approved by the US FDA.
An open label single arm multicenter expanded access treatment protocol with melflufen and dexamethasone for patients with:
- A clinically confirmed prior diagnosis of multiple myeloma with documented disease progression.
- Triple-class refractory multiple myeloma (TCR MM).
Triple-class refractory defined as refractory to at least one PI, at least one IMiD, and at least one Anti-CD38 mAb.
- Patients (with non-primary refractory MM) are required to have a minimum of at least 2 prior lines of therapy.
- Patients with primary refractory MM are eligible if they meet the criteria for TCR MM. They may meet these criteria for TCR MM if they have received at least one PI, at least one IMiD, and at least one Anti-CD38 mAb in their first line treatment or have had at least 2 prior lines of therapy.1
sEAPort is currently open for enrollment.2
To provide early access to melflufen treatment for eligible patients before commercial approval.
To evaluate safety and tolerability data of melflufen in combination with dexamethasone.
Secondary Objectives (Recommended / Optional):
To evaluate activity in patients treated with melflufen in combination with dexamethasone, by physician assessment.
Other optional assessments will also include collection of patient reported outcomes (PRO).
sEAPort (OP-110): Key Eligibility Criteria1*
Key Inclusion Criteria*
- Triple-class refractory defined as refractory to at least one PI, at least one IMiD, and at least one Anti-CD38 mAb. Patients (with non-primary refractory MM) are required to have a minimum of at least 2 prior lines of therapy
- Patients with primary refractory MM are eligible if they meet the criteria for TCR MM. They may meet this criteria for TCR MM if they have received at least one PI, at least one IMiD, and at least one Anti-CD38 mAb in their first line treatment or have had at least 2 prior lines of therapy.
- Eastern Cooperative Oncology Group (ECOG) ≤ 2
- Adequate organ function with the following laboratory results during screening (within 21 days) and immediately before treatment administration on Cycle1 Day1:
– Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
– Platelet count ≥ 75,000 cells/mm3 (75 x 109/L)
– Hemoglobin ≥ 8.0 g /dL (Red blood cell (RBC) transfusions are permitted)
– Total Bilirubin ≤ 1.5 x upper limit of normal (ULN), except patients diagnosed with Gilbert’s syndrome AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN
– Renal function: Estimated glomerular filtration rate (eGFR) by CKD-EPI formula of ≥ 45 mL/min
- Has not been enrolled in another melflufen clinical study and is not eligible for or does not have access to enroll in another ongoing clinical study of melflufen;
- Male patients: Agree to use contraception during the treatment period and for at least 3 months after the last dose of treatment and refrain from donating sperm during this period.
- Female patients: Eligible to participate if not pregnant or not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) or
- A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of treatment.
Key Exclusion Criteria*
- Known platelet transfusion refractory (i.e. platelet count fails to increase by > 10,000 cells/mm3 after a transfusion of an appropriate dose of platelets);
- Other malignancy diagnosed or requiring treatment within the past 3 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast, and very low and low risk prostate cancer patients in active surveillance.
- Concurrent known or suspected (symptomatic) amyloidosis or plasma cell leukemia.
- Any of the following treatments, within the specified timeframe:
- Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy.
- IMiDs, PIs and or corticosteroids within 2 weeks prior to initiation of therapy.
- Other investigational therapies within 4 weeks of initiation of therapy.
- Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to initiation of therapy.
- Prior stem cell transplant (autologous and/or allogeneic) within 6 months of initiation of therapy.
- Prior allogeneic stem cell transplant with active graft-versus-host- disease (GVHD);
- Prior major surgical procedure or radiation therapy within 4 weeks of the first dose of treatment (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy);
- Prior treatment with melflufen
*Key eligibility criteria listed and is not all inclusive
sEAPort is a verified Trial on SparkCures. 4
For more information on melflufen contact the Medical Information department directly by phone at 1-866-522-8894 or by email at email@example.com
Melflufen is an investigational agent and not currently approved by the US FDA.